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Tumor-associated proteases (TAPs) have 
become a central topic of interest in the 
scientifi c community because of their 
potential use as diagnostic and prognostic 
biomarkers and as drug targets. [ 2 ] Real-
time, in-vivo detection and monitoring of 
TAPs provide a powerful tool for the early 
diagnosis and screening of cancer. [ 3 ] More-
over, a real-time TAP probe would also be 
helpful for improving our understanding 
of its in-vivo biological functions. Cur-
rently however, TAP-specifi c probes for in-
vivo imaging remain rare. 
 Legumain (Enzyme Commission 
number: EC 3.4.22.34), an asparaginyl 
endopeptidase, is associated with malig-
nant tumor invasion, proliferation, and 
metastasis, and it is highly expressed in 
the majority of solid tumors, including 
those of breast, colon, and prostate can-
cers. [ 4 ] We also found that legumain is 
involved in a process from infl ammation 
to the development of malignant colon 
tumors (data not shown). Legumain has 
been actively investigated for its clinical 
use as a biomarker for diagnosis, [ 5 ] prog-
nosis, [ 5 ] and drug targeting. [ 6 ] Legumain 
can selectively hydrolyze the asparaginyl 
carboxyl terminal. [ 7 ] Such unique cleavage nature and its close 
association with cancer development and progression render 
legumain ideal as a target in the design of tumor-responsive 
prodrugs. [ 8 ] 
 Considering the importance of legumain, we present an 
activatable, legumain-responsive hybrid nanoprobe system for 
either in-vitro-cellular or in-vivo-tumor imaging based on the 
use of quantum dots (QDs) and the fl uorescence resonance 
energy transfer (FRET) effect ( Scheme  1 ). The hybrid nano-
probe system comprises two components: 1) QDs modifi ed 
with low-molecular-weight heparin (LH), labeled as QD-LH; 
and 2) the fl uorescence quencher “QSY21” conjugated to a pep-
tide sequence labeled PEP, which is low-molecular-weight pro-
tamine (LP) and a legumain-cleavable peptide linker. We pre-
viously reported the application of heparin–LP as a reversible 
linker between two macromolecular components (e.g., the tar-
geting antibody and enzyme drug) based on their charge inter-
action and affi nity. [ 9 ] Via the strong electrostatic affi nity of LH–
LP, the fl uorescent QD and quencher QSY21 can self-assemble 
into a hybrid nanoprobe, thereby forming a FRET system. Fol-
lowing intravenous (i.v.) administration, the nanoparticles will 
accumulate at the tumor target through the so-called “enhanced 
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 1.  Introduction 
 Proteases are involved in many biological and pathological 
processes via the regulatory mechanism of proteolysis, and 
consequently, they affect disease progression—typically in 
cancer, such as tumor angiogenesis, invasion, and metastasis. [ 1 ] 
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permeation and retention” (EPR) effect. [ 10 ] The peptide linker 
will then be cleaved by legumain in the tumor, releasing the 
QSY21 quencher, and rendering the fl uorescence of the recov-
ered QD. 
 The proposed hybrid probe system offers several major ben-
efi ts. First, conjugation of the donor and acceptor moieties at 
each end of a cleavable linker typically incurs extra effort and 
expense, due to the complicated synthesis route and the low 
yield. The automatic formation of the affi nity-based LH–LP 
linkage in our hybrid system may be what is needed to ease 
such synthesis problems. Secondly, the hybrid QD system 
could serve as a generic platform technique for the develop-
ment of imaging probes in the detection of various types of 
TAPs, simply by using a corresponding peptide linker that is 
specifi cally cleavable by the targeted protease to connect the 
QSY21 quencher to the LP, the LH binder. Last but not least, 
the nanoscale effect of the system allows for passive tumor tar-
geting and increased tumor accumulation of the probes via the 
EPR effect. 
 In our studies, the hybrid nanoprobe was examined for its 
legumain-activatable imaging function under various condi-
tions, including those of the cell culture, ex-vivo tumor slices, 
in-situ tissues, and in-vivo systemic targeted activation in the 
tumor. 
 2.  Results and Discussion 
 The releasable QSY21 quencher was conjugated to the ε-amino 
group of the lysine of a strategically designed chimeric pep-
tide (sequence: KPTNGGGVSRRRRRRGGRRRR; K: lysine, P: 
proline, T: threonine, N: asparagine, G: glycine, V: valine, S: 
serine, R: arginine) comprising a legumain-cleavable substrate 
and LP; the substrate sequence of PTN can be recognized and 
specifi cally cleaved by legumain. This conjugate was termed 
PEP-QSY. Triglycine (GGG), used as a fl exible peptide tether, 
was incorporated between the legumain-recognizable substrate 
(KPTN) and the LP (VSRRRRRRGGRRRR) in order to provide 
increased accessibility to the legumain-cleavable substrate, 
thereby enhancing the cleavage effi ciency. Via the electrostatic 
affi nity between LH and LP, the activatable QD-based FRET 
nanoprobe system (QD-LH/PEP-QSY, further abbreviated 
to  QD/QSY ) was formed. Fluorescence of the QD was sig-
nifi cantly inhibited by increasing the amount of the attached 
quencher of PEP-QSY, and the intensity was reduced to around 
10% when the  QD/QSY ratio reached 3:1, but with no further 
reduction in intensity beyond this ratio ( Figure  1 A). Hence, the 
ratio of 3:1 was selected for the subsequent investigations. The 
nanoprobe of  QD/QSY was characterized using dynamic light 
scattering (DLS) and transmission electron microscopy (TEM) 
(Figure  1 B,C). As shown in Figure  1 D, the fl uorescence of the 
nanoprobe remained stable for up to 120 h in both phosphate 
buffered saline (PBS) and cell culture medium (DMEM, Dul-
becco’s Modifi ed Eagle’s Medium) at 37 °C. The QD-LH and its 
FRET-based nanoprobe displayed remarkable biocompatibility 
with cells when using the model non-tumoral 293T cell line; 
nearly 80% cell viability was observed even at a nanoparticle 
concentration as high as 1.5 mg/mL in (Figure  1 E). The fi nd-
ings suggest the safety and potential of the nanoprobe for use 
in in-vivo studies. 
 A preliminary activation investigation was conducted by 
adding protamine to the  QD/QSY system. As previously dem-
onstrated by our study of the strategy termed ATTEMPTS (anti-
body-targeted, triggerable, electrically modifi ed prodrug-type 
strategy), [ 11 ] protamine has a stronger affi nity to LH than to LP 
and can thus cause the detachment of PEP-QSY component 
from the  QD/QSY complex. Over 80% recovery of the fl uores-
cence was achieved after the addition of an adequate amount 
of protamine to the  QD/QSY hybrid nanoprobe ( Figure  2 A,B), 
indicating the successful reversal of the deactivated FRET 
system. Subsequent to this study, enzymatic activation of the 
nanoprobe by legumain was examined. Fluorescence of the 
nanoprobe was effi ciently activated following by the addition of 
legumain (Figure  2 C,D). In contrast, almost no recovery of the 
fl uorescence was obtained when a non-specifi c enzyme trypsin 
was used, due to its inability to cleave away the quencher com-
ponent (PEP-QSY) from the QD/QSY (Figure  2 E,F), indicating 
the specifi city of activation of this system by legumain. 
 Cellular activation of the  QD/QSY system was per-
formed using both the normal HEK 293T cell line and the 
Adv. Funct. Mater. 2014, 24, 5443–5453
 Scheme 1.  Activatable nanoprobe comprises two components: 1) QD-LH: the ﬂ uorescence donor; and 2) the FRET quencher QSY21 coupled to a chi-
meric peptide (PEP) comprising LP and a legumain-cleavable sequence. The two components are linked via a tight but reversible electrostatic binding 
based on the LH–LP interaction, and thus form a FRET system (QD-LH/PEP-QSY), resulting in ﬂ uorescence quenching. The QSY21 quencher will 
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legumain-transfected HEK 293T cells (293T-Leg). Whereas the 
fl uorescence of the nanoprobe remained quenched in the normal 
HEK 293T cells, it was nevertheless signifi cantly activated in 
the 293T-Leg cells (Figure 3), suggesting the practicality of the 
nanoprobe in imaging legumain-positive cancer cells.  Whereas 
the fl uorescence of the nanoprobe remained quenched in the 
normal HEK 293T cells, it was nevertheless signifi cantly acti-
vated in the 293T-Leg cells ( Figure  3 ), suggesting the practicality 
of the nanoprobe in imaging legumain-positive cancer cells. 
 The cellular activation effi ciency of the nanoprobe was also 
examined in cellular cultures using a fl uorescence-activated 
cell sorter (FACS). The fl uorescence-positive percentage in the 
293T-Leg cells treated with varying concentrations of the probe 
was >90%, while that in the normal 293T cells was 25–39% 
( Figure  4 A,B). The median fl uorescence intensity in the 293T-
Leg cells was 2–3 times higher than that in normal 293T cells 
(Figure  4 C). The FACS results demonstrate the legumain-
induced activation of the prodrug-type probe. The HEK 293T 
cells also had very minor legumain expression, as shown in 
Figure  4 D. Therefore, it caused slight activation. Moreover, 
the serum proteases may result in low non-specifi c activation. 
However, the increase in activation effi ciency in the HEK 293T-
Leg cells are very signifi cant compared to that in HEK 293T 
cells (e.g., 93% versus 25% at a nanoprobe concentration of 
80 µg/mL). 
 The activation process within the cell was further examined 
by using confocal laser scanning microscopy (CLSM). The initial 
fl uorescence activation of the nanoprobe apparently occurred 
on the membrane or in the extracellular space ( Figure  5 A,B); it 
was then transported into the cell (Figure  5 C,D). Interestingly, 
at the end of the study, the QD fl uorescence was transferred 
back to the extracellular space again, probably via the cellular 
event of exocytosis. Our previous observations indicated that a 
QD could be exocytosed with a half-life of 21 min. [ 12 ] Formation 
of the active legumain is a pH-dependent multi-step process in 
the endosome/lysosome system. [ 13 ] The mature legumain pre-
sent in the cell membrane and released into the extracellular 
space is believed to control extracellular matrix remodeling. [ 14 ] 
Our observations provided additional evidence to support the 
extracellular enzymatic activity monitored by the nanoprobe. 
Adv. Funct. Mater. 2014, 24, 5443–5453
 Figure 1.  Characterization of the  QD/QSY system (QD-LH/PEP-QSY). A) Enhanced ﬂ uorescence quenching efﬁ ciency related to the increase of the 
 QD/QSY ratios. B) Particle size of  QD/QSY nanoprobe determined by DSL. C) TEM images of a) LH-modiﬁ ed QDs and b,c) the  QD/QSY nanoprobe. 
D) QD-LH and the nanoprobe remained stable in PBS and DMEM cultured medium, as indicated by the ﬂ uorescence. E) Cell-viability studies showing 










wileyonlinelibrary.com © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
 The tissue-specifi c activation of the prodrug-type probe 
was examined ex vivo using tissue cryosectioning slices that 
included the tumor and major organs collected from the mice 
harboring the human colon SW620 xenograft tumor with legu-
main overexpression. The probe concentration was 160 µg/mL. 
As expected, activation of the quenched nanoprobe thereby 
yielding fl uorescence occurred within these tumor slices 
( Figure  6 ). In contrast, fl uorescence was not observed in the 
glutaraldehyde-pretreated tumor slices, because of the dena-
turation of legumain by glutaraldehyde. This further confi rmed 
the enzyme-related activation process. Moreover, fl uorescence 
activation was not found in slices of major organs, apparently 
due to the lack of legumain expression in these tissues. These 
ex-vivo fi ndings were in good agreement with the in-vitro 
results, yielding strong support for the selective and specifi c 
imaging of legumain-presenting tumor tissues by the hybrid 
nanoprobe. 
 To examine the nanoprobe system in situ, mice bearing 
legumain-overexpressed colon SW620 xenograft tumor were 
used to study the activation event. As displayed in  Figure  7 A 
and B, the fl uorescence intensity peaked 11 min after peritu-
moral injection of the probe, with the ROI (region of interest) 
value of 2.267 × 10 6 , clearly defi ning the target from its sur-
roundings. However, the back (or spine) also displayed fl uo-
rescence signals after 11 min. Because it is at the higher posi-
tion and is closer to the light source and charge-coupled device 
(CCD) camera compared to other organs or tissues, it usually 
causes the increased refraction of light and the strengthened 
signals, particularly when using the fl uorescence probe with 
emission wavelength less than 700 nm. Moreover, in order to 
evaluate the effect of non-specifi c in-vivo activation, the probe 
was administered via intramuscular injection through the left 
thigh to the same animal at the 24-min mark after the animal 
receiving peritumoral administration. As shown in Figure  7 C, 
Adv. Funct. Mater. 2014, 24, 5443–5453
 Figure 2.  Activation of the  QD/QSY nanoprobe (QD-LH/PEP-QSY). A) Fluorescence recovery can be triggered by adding enough protamine to sub-
stitute the PEP-QSY of the  QD/QSY nanoprobe. B) Enhanced ﬂ uorescence recovery by increasing the amount of protamine. C) Fluorescence recovery 
triggered by legumain. D) Enhanced ﬂ uorescence recovery by increasing the concentration of legumain. E) Only minor ﬂ uorescence recovery was trig-
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merely a slight activation was detected, estimated from the peak 
fl uorescence intensity at the muscle injection site. The results 
further confi rmed that activation of the FRET-based nanoprobe 
could primarily be activated specifi cally at the tumor site, due to 
the presence of the overexpressed legumain. 
 To examine the practical feasibility and applicability of 
the nanoprobe for in-vivo imaging and legumain-detection, 
quenched nanoprobe was administered through the conven-
tional tail-vein route. Under such conditions, the preferential 
tumor accumulation of the nanoprobe could be obtained by 
taking the advantage of the tumor-associated EPR effect. As 
revealed in  Figure  8 A, the fl uorescence intensity in the tumor 
signifi cantly increased with time—from 0.5 to 2 h; it then pla-
teaued until the 24-h mark, clearly distinguishing the tumor 
from other tissues. Normalized fl uorescence intensity showed 
that the fl uorescence signal in the tumor 24 h after i.v. injec-
tion was 1.62 times stronger than that at 0.5 h (Figure  8 B). The 
major organs were collected 24 h after i.v. injection to better 
monitor tissue-specifi c activation of the nanoprobe. The nor-
malized fl uorescence intensity showed that the signal in the 
ex-vivo tumor was 6.0, 2.3, 4.7, 3.4, 5.8, and 4.9 times stronger 
than that in the heart, liver, spleen, kidney, and brain, respec-
tively (Figure  8 C,D). It should be pointed out that the fl uores-
cence distribution in the normal organs was mainly caused 
by the metabolic degradation of the peptide-based quencher 
and non-specifi c cleavage of the linker, thereby contributing to 
mild non-specifi c activation. Taken together, these results fur-
ther demonstrate the potential and in-vivo applicability of the 
 QD/QSY nanoprobe in the selective detection of legumain-
presenting tumors by responding to the legumain-rich tumor 
microenvironments. 
 A primary benefi t of this  QD/QSY nanoprobe system lies in 
the universal applicability of the established hybrid construc-
tion method. This method possesses great versatility and utility 
Adv. Funct. Mater. 2014, 24, 5443–5453
 Figure 3.  Activation of the  QD/QSY nanoprobe at varying concentrations (0, 80, 160 μg/mL) in the HEK 293T cell line and the legumain-transfected 
HEK 293T cells (293T-Leg). Images presented are bright-ﬁ eld, red ﬂ uorescence (Fluor (QD)), blue ﬂ uorescence (DAPI = 4′,6-diamidino-2-phenylindole), 
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for fabricating a variety of activatable QD systems targeting 
different TAPs. Indeed, aside from legumain, we also demon-
strated the feasibility for in-vivo detection of other TAPs, such 
as matrix metalloproteinase 2 (MMP-2), simply by substituting 
the original legumain-cleavable peptide with a substrate cleav-
able by MMP-2 in the activatable QD system ( Figure  9 ). With 
this in mind, the presented adaptable strategy could lead to the 
development of a new paradigm of specially tailored QD-based 
imaging platforms for tumors carrying specifi c, overexpressed 
protease biomarkers. 
 The general mechanism for protease-activatable probe design 
is a FRET effect that is achieved by employing a substrate-pep-
tide as a cleavable linker between the FRET fl uorophore and 
quencher. To enhance peptide stability and reduce non-specifi c 
cleavage in vivo, the costly  D -forms of peptide sequences are 
necessary to ensure image quality, especially in those cases 
involving long peptides (e.g., hairpin structure). [ 15 ] However, 
although natural amino acids are used in our system, non-spe-
cifi c activation was insignifi cant, indicating the additional ben-
efi ts of our strategy. 
 3.  Conclusion 
 In summary, we report the development of a novel, protease-
responsive QD nanoprobe platform for detecting tumor-asso-
ciated protease biomarkers and for tumor 
imaging. Molecular imaging of legumain 
was successfully achieved under cellular, ex-
vivo tissue-slice, in-situ, and in-vivo condi-
tions, providing a promising tool for cancer 
detection. Importantly, based on the adapt-
ability of this hybrid nanoprobe construc-
tion technology, it is envisioned that this 
imaging system could be applied universally 
to monitor tumors with known specifi cally 
overexpressed TAPs, simply by using the cor-
responding protease-substrate peptide that 
serves as a linker between LMWP and the fl u-
orescence quencher. Unlike the conventional 
probes that typically need to be custom-made 
for each targeted, specifi c protease, the LH-
modifi ed QD serves as a universal fl uores-
cent moiety. The LH–LMWP-based affi nity 
linkage provides great convenience for the 
hybrid construction, easing the fabrication 
process. This is a versatile method for the 
Adv. Funct. Mater. 2014, 24, 5443–5453
 Figure 5.  The activation process as monitored by CLSM: images at a) 49, b) 62, c) 64, d) 74, 
e) 81, and f) 86 min.
 Figure 4.  FACS assay for legumain-induced activation of the  QD/QSY nanoprobe. Various nanoprobe concentrations (0, 80, and 160 μg/mL) were 
employed in the investigation. A) FACS results for normal 293T cell line, showing minor activation. B) FACS results for the legumain-transfected 293T 
cells (293-Leg), showing increased activation relative to the normal cell line (FL3-H: height of red ﬂ uorescence intensity). C) The median ﬂ uorescence 
intensity observed in the normal 293T cells and transfected 293T-Leg cells. D) Western blotting analysis, showing very minor legumain expression in 
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fabrication of a protease-activatable probe for in-vivo detection 
and tumor imaging. 
 4.  Experimental Section 
 Materials : NaBH 4 , Tellurium powder, CdCl 2 , NaIO 4 , and cysteamine 
hydrochloride were obtained from Sinopharm Chemical Reagent 
Co., Ltd. (Shanghai, China). MPA was obtained from Alfa Aesar 
(UK). LH (Enoxaparin Sodium) was obtained from Changshan 
Biochemical Pharmaceutical Co., Ltd (Shijiazhuang, China). GelRed 
was purchased from Biotium (Hayward, USA). Fetal bovine serum 
(FBS), DMEM, penicillin-streptomycin, 0.25% trypsin-EDTA solution 
(EDTA = ethylenediaminetetra-acetic acid), dimethyl sulfoxide 
(DMSO), QSY21-NHS (where NHS is  N -hydroxysuccinimide), and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
were obtained from Invitrogen (USA). The Micro BCA protein assay 
kit and trypan blue were acquired from the Beyotime Institute of 
Biotechnology (Haimen, China). All other reagents were of analytical 
grade. 
 Preparation of the Prodrug-Type Probe : 1) MPA-Coated CdTe Quantum 
Dots ( QD-MPA): Tellurium powder (0.2 mmol) and NaBH 4 (1.3 mmol) 
were heated at 80 °C for 1 h under the protection of N 2 in order to 
prepare the NaHTe solution. A CdCl 2 solution (0.2 mmol) and a MPA 
solution (0.34 mmol) were mixed togetherb and the pH was adjusted 
to 12. The NaHTe solution (0.02 mmol) was added to the Cd precursor 
solution at a reaction ratio of 1:1.7:0.1 (Cd:MPA:Te). The reaction 
 Figure 6.  Ex-vivo detection of the tumor-speciﬁ c nanoprobe activation. Images presented are bright-ﬁ eld, red ﬂ uorescence (QD), blue ﬂ uorescence 
(DAPI), and merged (Overlap) images. The FRET-based nanoprobe was activated in legumain-presenting tumor tissue (cryosection slide), but it was 
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mixture was then heated to reﬂ ux under N 2 ﬂ ow. The thus-formed 
CdTe QDs were puriﬁ ed by precipitation using isopropanol, followed by 
vacuum drying. 
 Preparation of the Prodrug-Type Probe : 2) Thiol LH (LH-SH): LH 
(50 mg) was oxidized by sodium periodate in 10 mL of citric acid buffer 
(0.1  M , pH 7.0) at a molar ratio of 1:1.5 (NaIO 4 :(LH repeating unit)). 
After puriﬁ cation by dialysis, the product was reacted with cysteamine 
hydrochloride (11 mg) in 20 mL of phosphate buffer (0.1  M , pH 7.0). Thiol 
LH was obtained after reduction using sodium borohydride (125 mg) 
and puriﬁ cation by dialysis. 
 Preparation of the Prodrug-Type Probe : 3) Ligand-Exchange Reaction 
from QD-MPA to QD-LH: The LH-SH was added to the QD-MPA 
solution in PBS (pH 7.4), and incubated overnight at room temperature. 
The resultant QD-LH was puriﬁ ed by precipitation using isopropanol, 
followed by vacuum drying. 
 Preparation of the Prodrug-Type Probe : 4) Coupling of QSY21 
to PEP: The chimeric peptide of LP and the legumain-cleavable 
substrate was synthesized via a solid-state method (sequence: 
KPTNGGGVSRRRRRRGGRRRR, with N-terminal acetylated 
and C-terminal amidated, as denoted PEP). PEP in DMSO 
(10 μg/mL), via the ε-amino group on the terminal lysine, was reacted 
with the QSY21-NHS ester (1.3:1 mol/mol) in the presence of 1% 
 N -methylmorpholine for 48 h. The product of QSY21-PEP (or PEP-QSY) 
was determined and puriﬁ ed using reverse-phase C18 high-performance 
liquid chromatography (HPLC). For quantitative analysis of PEP-QSY, 
the HPLC conditions were: analytic HPLC system (Agilent-1200, USA) 
with a C18 column (4.6 mm × 250 mm, 5 μm);  λ = 210 nm; ﬂ ow rate of 
1 mL/min; gradient elution using H 2 O/(0.1% triﬂ uoroacetic acid (TFA)) 
and CH 3 CN/(0.1% TFA) as solvent A and B, and running from (95% 
A/5% B) to (30% A/70% B) in 30 min. The puriﬁ cation of PEP-QSY was 
performed by a preparative HPLC (Waters 1525 system, USA) with a 
C18 column (10 mm × 150 mm, 5 μm). Chromatographic conditions 
were as follows:  λ = 280 nm; ﬂ ow rate of 5 mL/min; gradient elution 
using H 2 O/(0.1% TFA) and CH 3 CN/(0.1% TFA) as solvent A and B, 
respectively, and running from (95% A/5% B) to (25% A/75%B) in 
10 min. 
 Preparation of the Prodrug-Type Probe : 5) Self-Assembly of PEP-QSY 
with QD-LH ( QD/QSY ): The self-assembly of PEP-QSY with QD-LH 
nanoparticles was prepared by mixing PEP-QSY, in a range of 0−32 μg, 
with QD-LH (32 μg) in deionized water. The mixtures were incubated 
for 30 min at room temperature. The FRET efﬁ ciency related to the 
addition of the quencher (PEP-QSY) was monitored by measuring the 
ﬂ uorescence intensity using a ﬂ uorospectrometer (Hitachi F4600, 
Japan). 
 Characterization of the Prodrug-Type Probe : The sulfhydryl content 
of the LH-SH was measured using Ellman’s reagent, according to the 
manufacturer’s protocol (Thermo Scientiﬁ c Piercer, USA). 
 Size analysis and the ξ potential of QD-LH were performed using 
a Zetasizer Nano-ZS90 (Malvern Instrument). The morphology was 
observed using TEM at an accelerating voltage of 100 kV (JEOL 
JEM-1200EX, Japan). Fluorescence intensity was measured on a 
ﬂ uorospectrometer (Hitachi, F4600, Japan). 
 Preliminary activation of the prodrug-type probe was carried out by 
adding protamine to competitively substitute the PEP-QSY and thus 
release QD-LH from the original self-assembly; ﬂ uorescence intensity 
was measured using the ﬂ uorospectrometer. 
 Figure 7.  In-vivo imaging following peritumoral and intramuscular injections. A) Fluorescence omages taken at various time points from 3 to 141 min 
following peritumoral injection of the nanoprobe. B) Plots for the ratios of the ﬂ uorescence intensity in the tumor versus in normal tissues following 
peritumoral injection. C) Fluorescence Images taken at various time points from 1 to 156 min following intramuscular injection of the nanoprobe. 
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 Colloidal stability of QD-LH and  QD/QSY was evaluated in 
both physiological PBS buffer and cell culture medium at 37 °C for 
up to 120 h; the ﬂ uorescence intensity was measured using the 
ﬂ uorospectrometer. 
 Cell Culture : Human embryonic kidney 293T cells were incubated in 
DMEM containing 10% FBS and 1% antibiotics at 37 °C in a humidiﬁ ed 
atmosphere and 5% CO 2 . 
 In-Vitro Cytotoxicity Assay of the Prodrug-Type Probe: The cytotoxicity 
was studied in the non-tumoral cell line of 293T. Cells were treated with a 
series of concentrations of the prodrug-type probe in 96-well plates with 
a standard MTT procedure. Absorbance was measured at 570 nm using 
a microplate reader (Thermo, USA). The cell viability was calculated 
according to the following equation, based on the optical densities of 
the sample, DMSO, and the control:
 
Cell viability(%)
(OD OD )/(OD OD ) 100%samples DMSO control DMSO
=
− − ×  
 Activation of the Prodrug-Type Probe using 293T-Leg Cell Lysates : 
Enzymatic activation was performed in the assay buffer (40 m M citric 
acid, 121 m M disodium phosphate dodecahydrate, 1 m M EDTA, 
0.1% 3-[(3-cholamidopropyl) dimethylammonio] propanesulfonate 
(CHAPS), 1 m M dithioreitol (DTT), pH 5.8), and the prodrug-type probe 
was incubated with the 293T-Leg cell lysates or trypsin at 37 °C for 
30 min. Fluorescence intensity of the activated QD were measured at 
an excitation wavelength of  λ ex = 260 nm and an emission wavelength 
of  λ em = 668 nm. 
 Cellular Activation of the Prodrug-Type Probe : Cell-speciﬁ c activation 
of the prodrug-type QD performed in the normal 293T cells and 
transfected 293T-Leg cells. The  QD/QSY was incubated with cells for 
5 h. Cells were then washed with PBS three times and ﬁ xed with 4% 
paraformaldehyde. Extracellular ﬂ uorescence was quenched using trypan 
blue. Cells were observed using a ﬂ uorescence microscope (Olympus, 
Japan). Furthermore, the uptake efﬁ ciency was quantitatively measured 
by FACS. In brief, normal 293T cells and transfected 293T-Leg cells were 
exposed to the medium containing the prodrug-type probe for 5 h. After 
washing with PBS, the cells were collected, and further washed with PBS 
three times. The cells were subjected to ﬂ uorescence analysis with FACS 
(BD, USA). 
 In-Vivo Animal Studies : Female BALB/c nude mice (4–5 weeks old, 
18–22 g) were housed under speciﬁ c pathogen-free conditions and in 
a 12 h light/dark cycle. Animals possessed free access to sterilized food 
pellets and distilled water. The experimental procedures were approved 
by the Institutional Animal Care and Use Committee. 
 Xenograft Tumor Mouse Models : Human colon cancer SW620 cells 
were incubated in RMPI 1640 medium containing 10% FBS, and 1% 
antibiotics at 37 °C under a humidiﬁ ed atmosphere and 5% CO 2 . A 
xenograft tumor model was established by inoculating 1 × 10 6 SW620 
cells subcutaneously into the back of nude mice. 
 Tissue-Specifi c Activatio n : Mice were humanely killed and the major 
organs (heart, liver, spleen, lung, kidney, and tumor) collected for 
cryosectioning. The tissue slices were divided into two experimental 
groups: the non-treatment slices, and the enzyme-inactivated slices 
that were pretreated with 4% glutaraldehyde to denature legumain. The 
slides were exposed to the prodrug-type nanoprobe (160 μg/mL) for 
30 min at room temperature, and then the activated ﬂ uorescence was 
imaged with a ﬂ uorescence microscope (Olympus, Japan). 
 In-Vivo Imaging : The mice bearing the SW620 tumor were given the 
prodrug-type QD via peritumoral or intramuscular injection for in-situ 
activation and imaging studies. Fluorescent imaging of the QD that 
was activated by legumain was obtained using the IVIS imaging system 
(Caliper Life Science) and analyzed using Living Image (Caliper Life 
Sciences). Furthermore, tail vein intravenous injection was conducted 
for investigating the application in real-time tumor imaging. 
 Statistical Analysis : The quantitative data were expressed as mean 
± standard deviation (S.D.). Statistical analysis was performed by the 
Student’s  t -test. Statistical signiﬁ cance was inferred at a value of  P < 
0.05. 
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 Figure 8.  In-vivo imaging following tail i.v. injection. A) Fluorescence images taken at various time points after injection: 0.5 to 24 h. B) Normalized 
ratios of the ﬂ uorescence intensity in tumor versus other major tissues. C) Ex-vivo tissue imaging at the experimental endpoint. D) The ﬂ uorescence 
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